Analyzing Motus GI (NASDAQ:MOTS) & Haemonetics (NASDAQ:HAE)

Haemonetics (NYSE:HAE) and Motus GI (NASDAQ:MOTS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Earnings and Valuation

This table compares Haemonetics and Motus GI’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Haemonetics $967.58 million 6.07 $55.02 million $2.39 48.49
Motus GI $40,000.00 1,641.60 -$22.26 million ($1.23) -1.85

Haemonetics has higher revenue and earnings than Motus GI. Motus GI is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.


This table compares Haemonetics and Motus GI’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Haemonetics 6.90% 24.59% 12.34%
Motus GI N/A -143.60% -107.10%

Volatility and Risk

Haemonetics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Insider & Institutional Ownership

96.7% of Haemonetics shares are owned by institutional investors. Comparatively, 43.3% of Motus GI shares are owned by institutional investors. 1.3% of Haemonetics shares are owned by company insiders. Comparatively, 18.1% of Motus GI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Haemonetics and Motus GI, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics 0 0 6 0 3.00
Motus GI 0 0 2 0 3.00

Haemonetics presently has a consensus target price of $143.67, indicating a potential upside of 23.97%. Motus GI has a consensus target price of $7.67, indicating a potential upside of 236.26%. Given Motus GI’s higher possible upside, analysts clearly believe Motus GI is more favorable than Haemonetics.


Haemonetics beats Motus GI on 9 of the 13 factors compared between the two stocks.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company is based in Fort Lauderdale, Florida.

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with's FREE daily email newsletter.

Leave a Reply